Xilio Therapeutics Q4 2023 EPS $(0.64) Up From $(0.82) YoY
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care
Xilio Therapeutics Q4 2023 EPS $(0.64) Up From $(0.82) YoY
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/21/2022 | $7.00 | Buy | Chardan Capital Markets |
| 1/10/2022 | $36.00 | Buy | HC Wainwright & Co. |
| 11/16/2021 | $40.00 | Buy | Guggenheim |
| 11/16/2021 | $31.00 | Outperform | Raymond James |
| 11/16/2021 | Outperform | Cowen & Co. | |
| 11/16/2021 | $32.00 | Overweight | Morgan Stanley |
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
10-Q - Xilio Therapeutics, Inc. (0001840233) (Filer)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors Treatment-related adverse events primarily Grade 1-2 at doses up to 4 mg/kg administered once every three weeks in outpatient setting, with no reported signs or symptoms of vascular leak syndrome Two patients continuing treatment for more than 1 year, demonstrating XTX202 was well-tolerated with repeated, long-term dosing Plan to evaluate XTX202 as a monotherapy in ongoing Phase 2 proof-of-concept trial at 4.0 mg/kg in patients with advanced melanoma and renal cell carci
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. The call will feature
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
-SEC Filing
WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that initial data from its Phase 1C dose escalation of XTX101 (vilastobart) in combination with atezolizumab in patients with advanced solid tumors will be presented in a late-breaker poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. Poster presentation details: Title: Phase 1/2 Study of Vilastobart (formerly XTX101), a Tumor-Activated, Fc-enhanced Anti-CTL
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format. Poster presentation details: Title: Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent act
WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock options to purchase an aggregate of 101,000 shares of its common stock to three new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.75 per share, which is equal to the closing price of the company's common stock on October 1, 2024. Each stock option will have a ten-
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company's board of directors. "On behalf of the entire board of directors, it is a privilege to welcome Aoife and James, both well-recognized biotech industry veterans, to the board of directors," said Paul Clancy, chair of the board of directors of Xilio Therapeutics. "Their extensive experience spanning all stages of drug development will be invaluable as Xilio progresses its
XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with no signs of vascular leak syndrome XTX301, a tumor-activated IL-12, received FDA clearance for IND application; anticipate initiating patient dosing in Phase 1 clinical trial in first quarter of 2023 Plan to focus resources on advancing clinical-stage cytokine programs and will seek to partner XTX101, a tumor-activated anti-CTLA-4, to advance beyond ongoing Phase 1 monotherapy cohorts $139.1 million in cash and cash equivalents as of September 30, 2022, with anticipate
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the company's board of directors. Mr. Heyman is a biopharmaceutical veteran with nearly 40 years of leadership and management expertise in corporate strategy, business development and venture capital from his tenure with Johnson & Johnson (J&J). In addition, the company announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, will serve as a strategic advisor to Xilio's board of directors and its executive team.
Chardan Capital Markets initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $7.00
HC Wainwright & Co. initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $36.00
Guggenheim initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $40.00
SC 13G - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G - Xilio Therapeutics, Inc. (0001840233) (Subject)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)